TP53 and acute myeloid leukemia: Overall, the study provides valuable insights into the cooperative effects of HSC age, TP53 mutations, and MDM2 haploinsufficiency, paving the way for more targeted therapeutic strategies for TP53-mutant AML and deepening our understanding of hematopoietic malignancies [641].